| Clinical Dose | 350mg |
| Source | Palmitoylethanolamide (PEA) |
| Organic Limits | Generic PEA is poorly bioavailable, so hard to ingest sufficient quantities as part of a balanced diet |
| Value | Levagen®+ increases the bioavailability of PEA by 1.75 times compared to standard |
| Benefits | Anti inflammatory |
| Technology | Due to its fatty nature, PEA has poor absorption in the body. LipiSperse® is a revolutionary technology that results in superior absorption and format breadth. |
| Region | Malaysia |
| Data | Several peer-reviewed clinical trials |
Levagen®+ is a patented ingredient that contains palmitoylethanolamide (PEA), a fatty acid that has huge benefits for joint health and sports recovery among other things. PEA can be found in some foods - soybeans, peanuts, egg yolk - but Levagen®+ is proven to be more bioavailable and potent than any amount of PEA you might find elsewhere in your diet or via supplementation.
Palmic Acid Monoethanolamide is another name for palmitoylethanolamide, which is often abbreviated to PEA. PEA is not derived from the similar sounding legume, so don't confuse this with pea protein: PEA is a type of fatty acid that the body produces naturally, but production decreases as we age: PEA is the reason why, when you fall or injure yourself when you're younger, you're able to pick yourself up easier, and your body heals better. PEA has been found in studies to be anti-inflammatory and neuroprotective, and is known as the 'bliss molecule' for the way it soothes and improves the body. LYMA's tenth ingredient Levagen®+ is a patented version of PEA.
Levagen®+ is a patented version of PEA (palmitoylethanolamide), sourced from palm kernel oil, and contains no allergenic ingredients. It is particularly bioavailable due to Levagen®+ including LipiSperse ® technology, meaning the body is able to absorb it better than in other forms.
PEA works as a highly localised and fleetingly active hormone, with a specific purpose: to act as protection, reducing pain and inflammation when and where tissues are damaged. Without PEA, even the smallest injury would be incapacitating.
Due to our modern lifestyles, the body may not be making as much PEA as it should. This means that we end up with more inflammation and pain than we deserve. Taking a PEA supplement restores the balance, pushing inflammation, pain and injury into the background. In other words it is a natural pain-killer.
According to studies into PEA, “no serious side effects have been reported” to supplementing with Palmitoylethanolamide, which Levagen®+ is a patented variation of.
The LYMA Supplement Starter Kit includes 30-day supply, copper storage vessel and membership that gives access to member pricing and benefits.
Monthly subscription from $199/USD
Shop Supplement1. The Effect of a Dispersible Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Joint Pain in an Adult Population – A Randomised, Double-Blind Study. Briskey, D., Roche, G. and Rao, A. International Journal of Nutrition and Food Sciences. 2020;10(1):9-13.
2. The Effect of Orally Dosed Levagen+ (palmitoylethanolamide) on Exercise Recovery in Healthy Males – A Double-Blind, Randomised, Placebo-Controlled Study. Mallard, A., Briskey, D., Richards, A., Mills, D. and Rao, A. Nutrients. 2020;12(3).
3. Efficacy of Palmitoylethanolamide (Levagen+) Compared to Ibuprofen for Reducing Headache Pain Severity and Duration in Healthy Adults: A Double Blind, Parallel, Randomized Clinical Trial. Briskey, D., Ebelt, P., Steels, E., Subah, S., Bogoda, N. and Rao, A. Food and Nutrition Sciences. 2022;13(1):690-701.
4. A Pharmacokinetic Study Showing the Increased Absorption of Palmitoylethanolamide using LipiSperse. Briskey, D., Mallard, A.R. and Rao, A. Journal of Nutraceuticals and Food Science. 2020;5(2):3.
5. Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomised Controlled Trial. Fessler, S.N., Liu, L., Chang, Y., Yip, T. and Johnston, C.S. The Journal of Nutrition. 2022;152(10):2218-2226.
6. Palmitoylethanolamide for Sleep Disturbance. A Double-Blind, Randomised, Placebo-Controlled Interventional Study. Rao, A., Ebelt, P., Mallard, A. and Briskey, D. Sleep Science and Practice. 2021;5(1):12.
